4.6 Article

Barriers and Enablers for Continuous Improvement Methodologies within the Irish Pharmaceutical Industry

期刊

PROCESSES
卷 10, 期 1, 页码 -

出版社

MDPI
DOI: 10.3390/pr10010073

关键词

continuous improvement; pharmaceutical industry; biopharmaceutical industry; lean six sigma; 21 CFR 211; 21 CFR 210; International Conference for Harmonisation (ICH); Pharmaceutical Quality System (PQS); European Medicines Agency; Food and Drug Administration

向作者/读者索取更多资源

This study investigates the barriers to implementing continuous improvement methodologies in the Irish Pharma industry, finding that a highly regulated environment is perceived as a significant obstacle. However, a majority of participants still utilize continuous improvement methods, driven by a desire to improve productivity and quality.
This study aims to investigate the barriers that exist when implementing continuous improvement methodologies, such as Lean Six Sigma (LSS), within the Irish Pharma industry. The main finding of this study is that 45% of participants perceived that a highly regulated environment could be a barrier to continuous improvement implementation, while 97% of respondents utilised Continuous improvement (CI) methods, such as Lean, Six Sigma, and LSS, within their organisations. While the International Conference of Harmonisation integrates CI into its Pharmaceutical Quality Systems (PQS) regulations, the highest motivation for CI implementation amongst the Irish Pharma industry is to improve Productivity and Quality. The main obstacles highlighted for CI implementation in Pharma attributed to stringent regulatory regimes were fear of extra validation activity, a compliance versus quality culture, and a regulatory culture of being safe. Another relevant finding presented in this paper is that participants CI LSS tools are very strongly integrated into the pharma industries corrective and preventative action system, deviations, and internal audit systems. Limitations of the research are that all the data collected in the survey came from professionals working for multinational Pharmaceutical companies based in Ireland. The authors understand that this is the first research focused on the barriers and status of CI initiatives in the pharmaceutical industry. The results of this study represent an important step towards understanding the enablers and obstacles for the use of continuous improvement methodologies in pharmaceutical manufacturing industries on a global scale.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据